HOME
PORTFOLIO
TEAM
FAQ
DIFFERENTIATION
SURF BREAK
START-UP GATEWAY
More
Carlsmed (NASDAQ:CARL) reported second-quarter 2026 revenue of $18.9 million, up 57% from $12.1 million a year earlier, as growth in its aprevo lumbar platform and contributions from its newer cervical offering lifted procedure volumes.
Portfolio Company
Carlsmed Q2 Earnings Call Highlights ...
Yahoo Finance
Aug 5, 2026
Epitel Secures $26 Million Series B to Expand Remote Wireless EEG Monitoring ...
Jul 28, 2026
Tombot Closes $7 Million Series A3 Growth Financing to Scale Operations and Expa ...
Businesswire
Jun 25, 2026
